Ra Pharmaceuticals Inc. (Nasdaq:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, visits the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).
Ra Pharmaceuticals Inc. (Nasdaq:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, visits the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).